Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients

Neuropsychobiology

Volumn 47, Issue 2, 2003, Pages 73-77

  Gross, Andres ^a,b,g   Joffe, Grigori ^a,b   Joutsiniemi, Sirkka Liisa ^b,c   Nyberg, Peter ^d,e   Rimón, Ranan ^f   Appelberg, Björn ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Tammiharju Mental Hospital   (Finland)

^c AALTO UNIVERSITY   (Finland)

^d Finska Lo karforeningen Duodecim   (Finland)

^e Meltola Hospital   (Finland)

^f Department of Psychiatry ^*  (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Clozapine; EEG; Monocytes; Reactive oxygen species; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOKINE; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; FEMALE; HUMAN; MALE; MICROGLIA; MONOCYTE; NEUROMODULATION; PARAMETER; PRIORITY JOURNAL; SCHIZOPHRENIA; STIMULATION; THETA RHYTHM;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MONOCYTES; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA; TIME FACTORS;

EID: 0037269773     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070012     Document Type: Article

References (38)

1. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26.
2. Meltzer HY: Treatment of the neuroleptic-non-responsive schizophrenic patient. Schizophr Bull 1992;18:515-542.
3. Kane JM, Honigfeld G, Singer J, Meltzer HY, and the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796.
4. De Lisi LE, Sakuma M, Tew K, Kushner M, Hoff A, Grimson R: Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 1997;74:129-140.
5. Fischer V, Haar JA, Greiner RV, Loyd RP: Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Mol Pharmacol 1991;40:846-853.
6. Maes M, Meltzer HY, Bosmans E: Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994;89:346-351.
7. Amsler H, Teerenhovi L, Barth E, Harjula K, Vuopio P: Agranulocytosis in patients treated with clozapine: A study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-248.
8. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I: Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977;11:193-198.
9. Smith R: A comprehensive macrophage T-lymphocyte theory of schizophrenia. Med Hypothesis 1993;39:248-257.
10. Ganguli R, Brar JS, Chengpappa KNR, De Leo M, Yang ZW, Shurin G, Rabin BS: Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch Gen Psychiatry 1995;52:668-672.
11. Melamed Y, Sirota P, Dicker DR, Fishman P: Superoxide anion production by neutrophils derived from peripheral blood of schizophrenic patients. Psychiatry Res 1998;77:29-34.
12. Gerez M, Tello A: Selected Quantitative EEG (QEEG) and event-related potential (ERP) variables as discriminators for positive and negative schizophrenia. Biol Psychiatry 1995; 38:34-49.
13. Omori M, Koshino Y, Murata T, Murata I, Nishio M, Sakamoto K, Horie T, Isaki K: Quantitative EEG in never-treated schizophrenic patients. Biol Psychiatry 1995;38:305-309.
14. Small JG, Milstein V, Small IF, Miller MJ, Kellams JJ, Corsaro CJ: Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment-resistant schizophrenia. Clin Electroencephalogr 1987;18:124-135.
15. Czobor P, Volavka J: Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Res 1992;42:129-144.
16. Tiihonen J, Nousiainen U, Hakola P, Leinonen E, Tuunainen A, Mervaala E, Paanila J: EEG abnormalities associated with clozapine treatment. Am J Psychiatry 1991;148:1406.
17. Williamson P, Mamelak M: Frontal spectral EEG findings in acutely ill schizophrenics. Biol Psychiatry 1987;22:1021-1024.
18. Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 1991;41:369-371.
19. Galderisi S, Maj M, Mucci A, Bucci P, Kemali D: QEEG alpha 1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biol Psychiatry 1994;35:367-374.
20. Joutsiniemi SL, Gross A, Appelberg B: Marked clozapine-induced slowing of EEG background over frontal, central, and parietal scalp areas in schizophrenic patients. J Clin Neurophysiol 2001;18:9-13.
21. Joffe G, Nyberg P, Gross A, Appelberg B: Is there an association between the effect of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia? Hum Psychopharmacol 1998;13:231-237.
22. Joffe G, Nyberg P, Gross A, Appelberg B: Clozapine-induced decrease in the production of reactive oxygen metabolites by monocytes in vitro may predict response to clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol Clin Exp 1999;14:203-209.
23. Andrejkovic AV, Nikolic B, Pachter JS, Zecevic N: Macrophages/microglia cells in human central nervous system during development: An immunohistochemical study. Brain Res 1998;814:13-25.
24. Chao CC, Hu S, Peterson PK: Modulation of human microglial cell superoxide production by cytokines. J Leuk Biol 1995;58:65-70.
25. Langermans JAM, Hazenbos WLW, Van Furth R: Antimicrobial functions of mononuclear phagocytes. J Immunol Methods 1994;174: 185-194.
26. Kay S, Fiszbein A, Opler L: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
27. De Chatelet LR, Long GD, Shirley PS, Bass DA, Thomas MJ, Hendersson FW, Cohen MS: Mechanism of the luminol-dependent chemiluminescence of human neutrophils. J Immunol 1982;129:1589-1593.
28. Ebert U, Oertel R, Kirch W: Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects. Clin Pharmacol Ther 2000;67:538-548.
29. Yamadera H, Kato M, Ueno T, Tsukahara Y, Okuma T: Pharmaco-EEG mapping of diazepam effects using different references and absolute and relative power. Pharmacopsychiatry 1993;26:254-258.
30. Radewicz K, Garey LJ, Reynolds R: Increase in microglia in frontal and temporal cortex of schizophrenics. Schizophr Res 1998;29:86-87.
31. Radewicz K, Garey LJ, Gentleman SM, Reynolds R: Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 2000;59:137-150.
32. Nikkilä HV, Müller K, Ahokas A, Miettinen K, Rimón R, Andersson L: Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry 1999;156:1725-1729.
33. Banati R, Gehrmann J, Schubert P, Kreutzberg G: Cytotoxicity of microglia. Glia 1993;7:111-118.
34. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K: Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 2000;14(Suppl 1):47-53.
35. Oken R: Towards a unifying hypothesis of neurodegenerative diseases and a concomitant rational strategy for their prophylaxis and therapy. Med Hypothesis 1995;45:341-342.
36. Dunn AJ, Wang J: Cytokine effects in CNS biogenic amines. Neuroimmunomodulation 1995;2:319-328.
37. Crochet S, Sakai K: Effects of microdialysis application of monoamines on the EEG and behavioural states in the cat mesopontine tegmentum. Eur J Neurosci 1999;11:3738-3752.
38. Sebban C, Zhang XQ, Tesolin-Decros B, Millan MJ, Spedding M: Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br J Pharmacol 1999;128:1045-1054.